ArticleThe Pan African medical journal2025
Locoregional recurrence of triple-negative breast cancer with low tumor-infiltrating lymphocytes: a case report.
Article in The Pan African medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is an aggressive subtype with high histological grade and an increased propensity for early recurrence. Early locoregional recurrence within three months of a Patey mastectomy is uncommon, making this case noteworthy and contributing valuable insight into the biological aggressiveness of TNBC and the prognostic role of tumor-infiltrating lymphocytes (TILs). We report the case of a 49-year-old postmenopausal woman followed for TNBC at the Mohammed VI Oncology Center in Casablanca, Morocco, who presented with a rapidly enlarging inflammatory mass along the outer edge of the left Patey mastectomy scar, extending toward the axillary tail, three months after surgery. Histopathological evaluation confirmed a locoregional recurrence of invasive carcinoma of no special type, revealing a 12.2 cm grade III tumor with a Ki-67 index of 40%, hormone receptor-negative/HER2-negative status, and low TILs (10%). The patient received neoadjuvant chemotherapy, followed by surgical excision of the recurrent lesion, radiotherapy and adjuvant chemotherapy consisting of capecitabine, vinorelbine, and gemcitabine, with good tolerance and no evidence of distant metastasis during follow-up. This case underscores the prognostic impact of low TILs and highlights the importance of considering the tumor microenvironment in risk stratification and personalized management of TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.